Letter to the editors-in-chief| Volume 48, ISSUE 5, P611-613, December 01, 1987

Desmopressin (DDAVP) in the treatment of deep vein thrombosis

      This paper is only available as a PDF. To read, Please Download here.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Tornebohm E.
        • Bratt G.
        • Grangqvist S.
        • Lockner D.
        • Egberg N.
        A pilot study: Desmopressin (DDAVP) in the treatment of DVT.
        Thromb. Res. 1987; 45: 635-643
        • Mannucci PM.
        • Aberg M.
        • Nilsson I.M.
        • Robertson B.
        Mechanisms of plasminogen activator and factor VIII increase after vasoactive drugs.
        Br. J. Haemat. 1975; 30: 81-93
        • Nilsson I.M.
        • Vilhardt H.
        • Holmberg L.
        • Astedt B.
        Association between factor VIII related antigen and plasminogen activator.
        Acta. Med. Scand. 1982; 211: 105-112
        • Bratt G.
        • Tornebohm E.
        • Granqvist S.
        • Aberg W.
        • Lockner D.
        A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.
        Thromb. Haemost. 1985; 54: 813-817
        • Melissari E.
        • Scully M.F.
        • Paes T.
        • Ellis V.
        • Kakkar V.V.
        The influence of DDAVP infusion on the coagulation and fibrinolytic response to surgery.
        Thromb. Haemost. 1986; 55: 54-57